1.Wang X, Chen Z, Xu J, Tang S, An N, Zhang Y, Zhang S, Zhang Q, Shen Y, Chen S, Lan X, Wang T, Zhai L, Cao S, Guo S, Liu Y, Bi A, Chen Y, Gai X, Duan Y, Zheng Y, Fu Y, Li Y, Yuan L, Tong L, Mo K, Wang M, Lin SH, Tan M, Luo C, Chen Y, Liu J, Zhang Q, Li L, Huang M*. SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors. Cell Res. 2022,32(7): 638-658. (Featured article, cover story).
2.Liu Z, Liu Y, Qian L, Jiang S, Gai X, Ye S, Chen Y, Wang X, Zhai L, Xu J, Pu C, Li J, He F, Huang M*, Tan M*. A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies. Mol Cell. 2021, 81(19): 4076-4090. (Featured article).
3.Jin N, Bi A, Lan X, Xu J, Wang X, Liu Y, Wang T, Tang S, Zeng H, Chen Z, Tan M, Ai J, Xie H, Zhang T, Liu D, Huang R, Song Y, Leung LH, Yao XJ, Ding J, Geng M*, Lin SH*, Huang M*. Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer. Nat Commun. 2019, 10(1): 2701.
4.Qu J, Sun W, Zhong J, Lv H, Zhu M, Xu J, Jin N, Xie Z, Tan M, Lin SH, Geng M, Ding J*, Huang M*. Phosphoglycerate mutase 1 regulates dNTP pool and promotes homologous recombination repair in cancer cells. J Cell Biol. 2017, 216(2):409-424. (Spotlight article）.
5.Zeng H, Qu J, Jin N, Xu J, Lin C, Chen Y, Yang X, He X, Tang S, Lan X, Yang X, Chen Z, Huang M*, Ding J*, Geng M*. Feedback activation of leukemia inhibitory factor receptor limits response to histone deacetylase inhibitors in breast cancer. Cancer Cell. 2016, 30(3): 459-73.
6.Sun W, Xie Z, Liu Y, Zhao D, Wu Z, Zhang D, Lv H, Tang S, Jin N, Jiang H, Tan M, Ding J, Luo C*, Li J*, Huang M*, Geng M*. JX06 selectively inhibits pyruvate dehydrogenase kinase PDK1 by a covalent cysteine modification. Cancer Res 2015, 75(22): 4923-36.
7.Zhang D, Jin N, Sun W, Li X, Liu B, Xie Z, Qu J, Xu J, Yang X, Su Y, Tang S, Han H, Chen D, Ding J, Tan M, Huang M*, Geng M*. Phosphoglycerate mutase 1 promotes cancer cell migration independent of its metabolic activity. Oncogene. 2017, 36(20): 2900-2909.
8.Huang M, Shen A, Ding J*, Geng M*. Molecularly targeted cancer therapy: some lessons from the past decade. Trends Pharmacol Sci. 2014; 35(1): 41-50. Invited review.
9.Huang M, Kim JM, Shiotani B, Yang K, Zou L, D'Andrea AD. The FANCM/FAAP24 Complex Is Required for the DNA Interstrand Crosslink-Induced Checkpoint Response. Mol Cell. 2010, 39(2): 259-268.
10.Huang M, Gao H, Chen Y, Zhu H, Cai Y, Zhang X, Miao Z, Jiang H, Zhang J, Shen H, Lin L, Lu W, Ding J. Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo. Clin Cancer Res. 2007, 13(4): 1298-1307. (Cover story).
